Fate Therapeutics Cm (FATE) 1.99 $FATE Arena (ARNA) Q2

New Post Public Reply Private Reply Replies (0) Message Board

Aug 2, 2016 at 2:18 AM

Fate Therapeutics Cm (FATE) 1.99 $FATE

Arena (ARNA) Q2 Earnings: What's in Store for the Stock?
Arpita Dutt - Zacks Investment Research - Mon Aug 01, 7:56AM CDT
Will an improvement in Belviq's performance help Arena (ARNA) deliver a surprise in Q2?
FATE: 1.99 (-0.08), ARNA: 1.68 (+0.01), EXEL: 9.27 (+0.09)

Geron (GERN) Q2 Earnings: What's in Store for the Stock?
Arpita Dutt - Zacks Investment Research - Mon Aug 01, 7:38AM CDT
With Geron (GERN) being a development stage company, investor focus will remain on imetelstat.
FATE: 1.99 (-0.08), JNJ: 125.40 (+0.17), GERN: 2.71 (+0.03), EXEL: 9.27 (+0.09)

Fate Therapeutics (FATE) Catches Eye: Stock Rises 5.9%
Zacks Equity Research - Zacks Investment Research - Fri Jul 29, 7:15AM CDT
Fate Therapeutics, Inc. (FATE) was a big mover last session, as its shares rose almost 6% on the day.
FATE: 1.99 (-0.08), ANIP: 61.06 (+0.46)

Fate Therapeutics Announces Issuance of U.S. Patent on Compositions of Human Induced Pluripotent Cells
GlobeNewswire - Tue Jul 26, 7:02AM CDT
Key Patent Covers Renewable Pluripotent Cell Source for Development of Off-the-Shelf NK- and T-Cell Immunotherapies
FATE: 1.99 (-0.08)

Fate's (FATE) ProTmune Gets Fast Track Status, Stock Up
Zacks Equity Research - Zacks Investment Research - Tue Jun 21, 10:46AM CDT
Fate Therapeutics (FATE) announced that the FDA has granted the Fast Track status to its immunotherapy ProTmune.
FATE: 1.99 (-0.08), ANIP: 61.06 (+0.46), RTRX: 18.17 (+0.24), ACOR: 25.13 (-0.15)

Fate Therapeutics (FATE) Catches Eye: Stock Jumps 19.1%
Zacks Equity Research - Zacks Investment Research - Tue Jun 21, 7:25AM CDT
Fate Therapeutics, Inc. (FATE) moved big last session, as its shares jumped over 19% on the day.
FATE: 1.99 (-0.08), NEO: 8.52 (-0.20)

Fate Therapeutics to Host Off-the-Shelf Cancer Immunotherapy Focus Session at 2016 Annual Meeting of International Society for Stem Cell Research
GlobeNewswire - Thu Jun 16, 7:01AM CDT
Fate Therapeutics, Inc. (NASDAQ:FATE), a biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced today that it will host a Focus Session entitled "Fighting Cancer with Off-the-Shelf iPSC Immunotherapies" at the 2016 Annual Meeting of the International Society for Stem Cell Research (ISSCR) on Wednesday, June 22, 2016 from 9:00 a.m. to 12:00 p.m. PT in San Francisco, California.
FATE: 1.99 (-0.08)

Fate Therapeutics Appoints Chris M. Storgard, M.D. as Chief Medical Officer
GlobeNewswire - Tue May 17, 7:01AM CDT
Fate Therapeutics, Inc. (NASDAQ:FATE), a biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, today announced that Chris M. Storgard, M.D. has joined the Company as its Chief Medical Officer. Dr. Storgard is an experienced drug development clinician with a proven history of advancing early stage programs through clinical development and product commercialization. As CMO, he will lead the design and execution of the Company's clinical trials for its programmed cellular immunotherapies.
FATE: 1.99 (-0.08)

Fate Therapeutics reports 1Q loss
Automated Insights - Mon May 09, 4:12PM CDT
SAN DIEGO (AP) _ Fate Therapeutics Inc. (FATE) on Monday reported a loss of $8.4 million in its first quarter.
FATE: 1.99 (-0.08)

Fate Therapeutics Reports First Quarter 2016 Financial Results
GlobeNewswire - Mon May 09, 3:01PM CDT
Phase 1/2 Clinical Trial of ProTmune(TM) for Prevention of Acute GvHD and CMV Infection to Begin Enrollment in mid-2016
FATE: 1.99 (-0.08)

Tissue Engineering Market To Reach $11.53 Billion By 2022 Owing To Increased Focus Of Stem Cell Therapies: Grand View Research, Inc.
GlobeNewswire - Thu May 05, 4:00AM CDT
Global tissue engineering market is expected to reach USD 11.53 billion by 2022, according to a new report by Grand View Research, Inc. The demand for tissue engineering is expected to upsurge owing to the shift of focus from stem cell therapies to immunocelluar therapies. Moreover, companies such as Caladrius and Celyad changed their names from Cardio3 Bio NeoStem respectively to reflect their focus on immunotherapies.
FATE: 1.99 (-0.08)

Fate Therapeutics to Webcast Conference Call Reporting First Quarter 2016 Financial Results on May 9, 2016
GlobeNewswire - Mon May 02, 3:01PM CDT
Fate Therapeutics, Inc. (NASDAQ:FATE), a biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced today that the Company will host a conference call and live audio webcast on Monday, May 9, 2016 at 5:00 p.m. ET to report its first quarter 2016 financial results and provide a corporate update.
FATE: 1.99 (-0.08)

Fate Therapeutics (FATE) Jumps: Stock Moves 6.5% Higher
Zacks Equity Research - Zacks Investment Research - Mon Apr 11, 7:15AM CDT
Fate Therapeutics, Inc. (FATE) shares rose almost 7% in the last trading session.
FATE: 1.99 (-0.08), ANIK: 50.64 (+0.72)

Fate Therapeutics to Present at the Needham & Company 15th Annual Healthcare Conference
GlobeNewswire - Tue Apr 05, 3:01PM CDT
Fate Therapeutics, Inc. (NASDAQ:FATE), a biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced today that Scott Wolchko, President and Chief Executive Officer, will be presenting a company overview at the Needham & Company 15th Annual Healthcare Conference in New York City on Tuesday, April 12, 2016 at 4:20 p.m. ET.
FATE: 1.99 (-0.08)

Vertex (VRTX) Down on CRL for Kalydeco Label Expansion
Arpita Dutt - Zacks Investment Research - Mon Feb 08, 4:38PM CST
The FDA informed Vertex (VRTX) that its sNDA for expanding the label of its CF treatment, Kalydeco, cannot be approved in its present form.
FATE: 1.99 (-0.08), VRTX: 98.20 (+1.20), LGND: 138.53 (+3.65), CELG: 114.69 (+2.50)

Novo Nordisk Posts In Line Q4 Earnings, Tops Revenues
Zacks Equity Research - Zacks Investment Research - Thu Feb 04, 12:40PM CST
Novo Nordisk (NVO) reported fourth quarter 2015 revenues that increased 2.3% year over year to $4.2 billion beating Zacks Consensus Estimate of $4.1 billion.
FATE: 1.99 (-0.08), NVO: 57.05 (+0.08), ATRA: 24.40 (+0.40), BXLT: 46.02 (-0.18)

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Pipeline Review, H2 2015
M2 - Thu Feb 04, 5:02AM CST
Research and Markets (http://www.researchandmarkets.com/research/trfcb9/acute_lymphocytic) has announced the addition of the "Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Overview - Therapeutics Development - Pipeline Products for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Overview - Pipeline Products for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Comparative Analysis - Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Therapeutics under Development by Companies - Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Therapeutics under Investigation by Universities/Institutes - Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Products under Development by Companies - Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Products under Investigation by Universities/Institutes - Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Companies Involved in Therapeutics Development Companies Mentioned - Partial List - 4SC AG - AbbVie Inc. - Actinium Pharmaceuticals, Inc. - Affimed Therapeutics AG - Altor BioScience Corporation - Amgen Inc. - Atara Biotherapeutics, Inc. - Baxalta Incorporated - Bellicum Pharmaceuticals, Inc. - Bexion Pharmaceuticals, LLC. - Bio-Path Holdings, Inc. - BioSight Ltd. - Bristol-Myers Squibb Company - Calithera Biosciences, Inc. - Cantargia AB - Celator Pharmaceuticals, Inc. - Cellectis S.A. - Cellular Biomedicine Group, Inc. - Ceronco Biosciences - Constellation Pharmaceuticals, Inc. - Cyclacel Pharmaceuticals, Inc. - Daiichi Sankyo Company, Limited - DiNonA Inc. - Effimune SAS - Eli Lilly and Company - Epirus Biopharmaceuticals, Inc. - EpiZyme, Inc. - Erytech Pharma SA - Eureka Therapeutics, Inc. - Fate Therapeutics, Inc. - Formula Pharmaceuticals, Inc. - Gamida Cell Ltd. - GlaxoSmithKline Plc - Hangzhou Minsheng Pharmaceutical Group Co.,Ltd For more information visit http://www.researchandmarkets.com/research/tr...ymphocytic
FATE: 1.99 (-0.08), AMGN: 174.16 (+2.13), EPZM: 10.35 (-0.01), LLY: 83.18 (+0.29), ATRA: 24.40 (+0.40), GSK: 45.25 (+0.18), BMY: 76.19 (+1.38), ATNM: 1.71 (-0.07), CYCC: 5.01 (-0.02), BLCM: 16.04 (+0.16), BPTH: 1.71 (+0.01), CALA: 3.15 (-0.02), ABBV: 66.94 (+0.71), BXLT: 46.02 (-0.18), CBMG: 14.82 (-0.07)

Fate Therapeutics to Present at Leerink Partners 5th Annual Global Healthcare Conference
GlobeNewswire - Wed Feb 03, 3:01PM CST
Fate Therapeutics, Inc. (NASDAQ:FATE), a biopharmaceutical company dedicated to the development of programmed cellular immunotherapeutics for cancer and immune disorders, announced today that Scott Wolchko, President and Chief Executive Officer, will be presenting a company overview at the Leerink Partners 5 Annual Global Healthcare Conference on Wednesday, February 10, 2016 at 1:25 p.m. ET in New York City.
FATE: 1.99 (-0.08)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

AST SpaceMobile Faces Class Action Over Misstatements

What's Going On with AST SpaceMobile? Kicking off with a heavy hitter here, folks. AST SpaceMobile, Inc., trading under NASDAQ:ASTS, is under a securities fraud spotlight. We're talking allegations piled higher than a morning stack of pancakes. If you picked up any ASTS shares between March 4, 2025, and July 15, 2026, you're in on this rough ride. There's a class action...

HONA Faces Legal Heat: Investor Lawsuit Over Losses

The Investor Storm Brewing Over Honeywell Aerospace There it is again, another industry heavyweight caught in a dizzying whirlwind of litigation. Honeywell Aerospace Inc. (NASDAQ:HONA), a name as established as an old boot in the business, now faces a class action lawsuit that's got investors frantically dusting off phone numbers for their attorneys. The Messy Allegations...

Cut Winter Heating Costs with Townsend's Rebate Help

Unseen Perils of Winter Heating in Massachusetts Massachusetts homeowners, listen up. If your heating system is older than the Model T, it's time to rethink your winter strategy. You don't want to be stuck in the cold when the thermometer hits single digits, do you? That's where Townsend comes in, making waves with their rebate assistance program. Navigating the Rebate...

Jackson Wang's Fantasy IP Hits Hong Kong Stage

A Star-Studded Fantasy Comes Alive Hong Kong isn't just about dim sum and skyline views—it's a magnet for celebrity showcases, and this time, Jackson Wang's pulling the strings. The guy's ventured beyond music and idol fame, diving head-first into creative visuals with his fantasy IP, "Under the Castle" (UTC). Pairing up with Ocean Park's Halloween Fest, he's cooked up...

Krispy Kreme Faces Legal Probe: Fiduciary Breach?

Diving Deep into the Krispy Kreme Allegations Look, this isn't your run-of-the-mill donut drama. When you hear rumblings of corporate missteps, especially ones that involve potential breaches of fiduciary duties, it's time to perk up those ears. Over at Krispy Kreme, Inc. (NASDAQ:DNUT), there's some heat in the kitchen, and it's not just from frying those glazed beauties....

Farm Aid 2026: A Resilient Tribute to Family Farmers

Shining a Light on Essential Family Farmers Every year, thousands gather for Farm Aid to back the unsung heroes who put food on our plates. In 2026, the scene shifted to the amphitheater at Virginia Beach, where an epic lineup of music took stage not just to entertain but to underline a critical issue—family farmers are fighting for survival. These folks aren't merely...

Quay Sunglasses: Luxury Looks, Affordable Prices

Ah, sunglasses—the quintessential accessory that screams both practicality and style. A million-dollar look without the million-dollar expense? That's where Quay comes in. They've been recognized by Expert Consumers, no less, as some of the best-in-class for affordable luxury eye candy out there—aimed at shoppers who want the designer vibe without the hemorrhaging...

Timur Turlov Leads FIDE with Chess and Digital Focus

An Unpredicted Victory in Samarkand Well, color me surprised. Timur Turlov's made waves by clinching the role of FIDE President at the General Assembly in Samarkand. This one's quite the turn for the chess world—Kazakhstan’s own stepping up to run the whole show. This isn't just some ceremonial post either. Turlov, who's been pulling strings over at the Kazakhstan...

China Southern Airlines Marks 70th Anniversary in NYC

Taking Flight with Legacy and Tradition Throwing a bash on Times Square isn't just about flash; it's about letting folks know you mean business. And China Southern Airlines has been doing just that for 70 years. Imagine starting from Guangzhou and ending up splashed across New York City's giant LED screens—talk about a journey! From Humble Roots to Global Network...

PACS Group Faces Legal Scrutiny: What to Watch

PACS Group: Legal Storm Brewing Welcome to the latest saga in the volatile theater of corporate governance. PACS Group, Inc., ticker symbol NYSE:PACS, is under the microscope, and not for debuting a groundbreaking product or hitting a stock milestone. Nope, instead we've got Halper Sadeh LLC out of New York investigating some possible hanky-panky from PACS directors and...